Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
NAFLD
NASH
RNAs
fibrosis
liquid-biopsy
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
20
12
2018
revised:
28
05
2019
accepted:
31
05
2019
pubmed:
7
6
2019
medline:
10
10
2020
entrez:
7
6
2019
Statut:
ppublish
Résumé
In patients with non-alcoholic fatty liver disease (NAFLD), liver biopsy is the gold standard to detect non-alcoholic steatohepatitis (NASH) and stage liver fibrosis. We aimed to identify differentially expressed mRNAs and non-coding RNAs in serum samples of biopsy-diagnosed mild and severe NAFLD patients with respect to controls and to each other. We first performed a whole transcriptome analysis through microarray (n = 12: four Control: CTRL; four mild NAFLD: NAS ≤ 4 F0; four severe NAFLD NAS ≥ 5 F3), followed by validation of selected transcripts through real-time PCRs in an independent internal cohort of 88 subjects (63 NAFLD, 25 CTRL) and in an external cohort of 50 NAFLD patients. A similar analysis was also performed on liver biopsies and HepG2 cells exposed to oleate:palmitate or only palmitate (cellular model of NAFL/NASH) at intracellular/extracellular levels. Transcript correlation with histological/clinical data was also analysed. We identified several differentially expressed coding/non-coding RNAs in each group of the study cohort. We validated the up-regulation of UBE2V1, BNIP3L mRNAs, RP11-128N14.5 lncRNA, TGFB2/TGFB2-OT1 coding/lncRNA in patients with NAS ≥ 5 (vs NAS ≤ 4) and the up-regulation of HBA2 mRNA, TGFB2/TGFB2-OT1 coding/lncRNA in patients with Fibrosis stages = 3-4 (vs F = 0-2). In in vitro models: UBE2V1, RP11-128N14.5 and TGFB2/TGFB2-OT1 had an increasing expression trend ranging from CTRL to oleate:palmitate or only palmitate-treated cells both at intracellular and extracellular level, while BNIP3L was up-regulated only at extracellular level. UBE2V1, RP11-128N14.5, TGFB2/TGFB2-OT1 and HBA2 up-regulation was also observed at histological level. UBE2V1, RP11-128N14.5, BNIP3L and TGFB2/TGFB2-OT1 correlated with histological/biochemical data. Combinations of TGFB2/TGFB2-OT1 + Fibrosis Index based on the four factors (FIB-4) showed an Area Under the Curve (AUC) of 0.891 (P = 3.00E-06) or TGFB2/TGFB2-OT1 + Fibroscan (AUC = 0.892, P = 2.00E-06) improved the detection of F = 3-4 with respect to F = 0-2 fibrosis stages. We identified specific serum coding/non-coding RNA profiles in severe and mild NAFLD patients that possibly mirror the molecular mechanisms underlying NAFLD progression towards NASH/fibrosis. TGFB2/TGFB2-OT1 detection improves FIB-4/Fibroscan diagnostic performance for advanced fibrosis discrimination.
Sections du résumé
BACKGROUND & AIMS
In patients with non-alcoholic fatty liver disease (NAFLD), liver biopsy is the gold standard to detect non-alcoholic steatohepatitis (NASH) and stage liver fibrosis. We aimed to identify differentially expressed mRNAs and non-coding RNAs in serum samples of biopsy-diagnosed mild and severe NAFLD patients with respect to controls and to each other.
METHODS
We first performed a whole transcriptome analysis through microarray (n = 12: four Control: CTRL; four mild NAFLD: NAS ≤ 4 F0; four severe NAFLD NAS ≥ 5 F3), followed by validation of selected transcripts through real-time PCRs in an independent internal cohort of 88 subjects (63 NAFLD, 25 CTRL) and in an external cohort of 50 NAFLD patients. A similar analysis was also performed on liver biopsies and HepG2 cells exposed to oleate:palmitate or only palmitate (cellular model of NAFL/NASH) at intracellular/extracellular levels. Transcript correlation with histological/clinical data was also analysed.
RESULTS
We identified several differentially expressed coding/non-coding RNAs in each group of the study cohort. We validated the up-regulation of UBE2V1, BNIP3L mRNAs, RP11-128N14.5 lncRNA, TGFB2/TGFB2-OT1 coding/lncRNA in patients with NAS ≥ 5 (vs NAS ≤ 4) and the up-regulation of HBA2 mRNA, TGFB2/TGFB2-OT1 coding/lncRNA in patients with Fibrosis stages = 3-4 (vs F = 0-2). In in vitro models: UBE2V1, RP11-128N14.5 and TGFB2/TGFB2-OT1 had an increasing expression trend ranging from CTRL to oleate:palmitate or only palmitate-treated cells both at intracellular and extracellular level, while BNIP3L was up-regulated only at extracellular level. UBE2V1, RP11-128N14.5, TGFB2/TGFB2-OT1 and HBA2 up-regulation was also observed at histological level. UBE2V1, RP11-128N14.5, BNIP3L and TGFB2/TGFB2-OT1 correlated with histological/biochemical data. Combinations of TGFB2/TGFB2-OT1 + Fibrosis Index based on the four factors (FIB-4) showed an Area Under the Curve (AUC) of 0.891 (P = 3.00E-06) or TGFB2/TGFB2-OT1 + Fibroscan (AUC = 0.892, P = 2.00E-06) improved the detection of F = 3-4 with respect to F = 0-2 fibrosis stages.
CONCLUSIONS
We identified specific serum coding/non-coding RNA profiles in severe and mild NAFLD patients that possibly mirror the molecular mechanisms underlying NAFLD progression towards NASH/fibrosis. TGFB2/TGFB2-OT1 detection improves FIB-4/Fibroscan diagnostic performance for advanced fibrosis discrimination.
Identifiants
pubmed: 31169972
doi: 10.1111/liv.14167
pmc: PMC6771597
doi:
Substances chimiques
Biomarkers
0
RNA, Untranslated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1742-1754Informations de copyright
© 2019 The Authors. Liver International Published by John Wiley & Sons Ltd.
Références
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3
pubmed: 29908364
Chem Biol Interact. 2007 Jan 30;165(2):106-16
pubmed: 17188672
Liver Int. 2019 Sep;39(9):1742-1754
pubmed: 31169972
Anticancer Res. 2013 Aug;33(8):3185-93
pubmed: 23898077
Scand J Gastroenterol. 2015 Mar;50(3):341-6
pubmed: 25540973
World J Gastroenterol. 2015 Jul 28;21(28):8527-40
pubmed: 26229396
Hepatology. 2014 Feb;59(2):471-82
pubmed: 23913408
World J Hepatol. 2015 Apr 8;7(4):638-48
pubmed: 25866601
Cell Biol Int. 2013 Sep;37(9):917-28
pubmed: 23619824
Circulation. 2008 Jan 22;117(3):396-404
pubmed: 18178777
Biochim Biophys Acta. 2009 Aug;1792(8):746-56
pubmed: 19539753
Mo Med. 2018 May-Jun;115(3):225-229
pubmed: 30228727
Sci Rep. 2017 May 15;7(1):1906
pubmed: 28507335
Hepatology. 2015 May;61(5):1565-78
pubmed: 25581263
Gastroenterology. 2016 Sep;151(3):513-525.e0
pubmed: 27318147
Clin Chem. 2001 Aug;47(8):1488-9
pubmed: 11468248
Liver Res. 2017 Sep;1(3):163-167
pubmed: 29576888
Sci Rep. 2017 Sep 19;7(1):11863
pubmed: 28928397
PLoS One. 2011;6(9):e24363
pubmed: 21931690
FEBS J. 2016 Jun;283(12):2219-32
pubmed: 26807763
Am J Pathol. 2007 Mar;170(3):967-80
pubmed: 17322381
Dis Markers. 2016;2016:9085195
pubmed: 27143813
Oncogene. 2008 Dec;27 Suppl 1:S114-27
pubmed: 19641497
Hepatology. 2017 Apr;65(4):1145-1155
pubmed: 27639088
Sci Rep. 2016 Oct 19;6:35531
pubmed: 27759039
Int J Mol Sci. 2018 Nov 28;19(12):
pubmed: 30487448
Clin Chem. 2002 Oct;48(10):1647-53
pubmed: 12324479
Int J Mol Med. 2018 Apr;41(4):1917-1930
pubmed: 29393369
Nutr Metab Cardiovasc Dis. 2016 Dec;26(12):1129-1139
pubmed: 27756518
Mol Cell Endocrinol. 2016 Sep 5;432:83-95
pubmed: 26525415
Hepatology. 2007 Aug;46(2):582-9
pubmed: 17661414
Gut Liver. 2012 Apr;6(2):149-71
pubmed: 22570745
PLoS One. 2014 Dec 23;9(12):e115849
pubmed: 25536043
Clin Med (Lond). 2018 Jun;18(3):245-250
pubmed: 29858436
Exp Mol Med. 2017 Jan 13;49(1):e283
pubmed: 28082742
Biochem J. 2008 Jun 1;412(2):179-90
pubmed: 18466115
Gut. 2009 Jun;58(6):825-32
pubmed: 18403495
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276
pubmed: 29307986
Oncotarget. 2016 Apr 12;7(15):19499-518
pubmed: 26799667
Hepatology. 2010 Jun;51(6):2127-39
pubmed: 20235334
Sci Rep. 2016 Mar 18;6:23343
pubmed: 26987697
J Hepatol. 2014 Jan;60(1):167-74
pubmed: 23973932
Int J Biochem Cell Biol. 2016 Oct;79:33-40
pubmed: 27506770
IUBMB Life. 2015 Nov;67(11):847-52
pubmed: 26472541
J Lipid Res. 2004 Oct;45(10):1846-51
pubmed: 15231850
Autophagy. 2015;11(12):2172-83
pubmed: 26565952
Exp Mol Med. 2018 Jan 19;50(1):e428
pubmed: 29350677
Hepatology. 2014 Feb;59(2):483-95
pubmed: 23996730
Mol Cancer. 2015 Jan 21;14:3
pubmed: 25608466